Based on recent data, Dermata Therapeutics, Inc. (DRMA) shows an Average True Range (ATR) of 0.33 and an Enterprise Value of -5.06M. Its average trading volume over the past 3 months is 2.02M, indicating liquidity. These fundamental metrics provide insight into DRMA's underlying financial health and market activity.
| ATR | 0.33 |
| Enterprise Value | -5.06M |
| Avg Vol (3 Months) | 2.02M |
| Avg Vol (10 Days) | 7.28M |
Dermata Therapeutics, Inc. (DRMA) technical indicators as of February 20, 2026: the SMA 20 is -37.24%, SMA 50 at -42.47%, and SMA 200 at -73.93%. The RSI 14 value is 35.05, suggesting its current momentum. These technical analysis signals help assess DRMA's price trends and potential future movements.
| SMA 20 | -37.24% |
| SMA 50 | -42.47% |
| SMA 200 | -73.93% |
| RSI 14 | 35.05 |
Dermata Therapeutics, Inc. (DRMA) stock performance overview as of February 20, 2026: The 52-week high is $63.33 (currently -94.68% below), and the 52-week low is $0.574 (currently -2.33% above). Over the past year, DRMA's performance is -83.68%, compared to the S&P 500's 7.5% change.
| 52-Week High | 63.33 |
| 52-Week High Chg | -94.68% |
| 52-Week Low | 0.5739 |
| 52-Week Low Chg | -2.33% |
| S&P 500 52-Week Chg | 7.5% |
According to market data, Dermata Therapeutics, Inc. (DRMA) stock's recent performance metrics show that over the last month, DRMA is -5.65%, with a Year-to-Date (YTD) performance of -6.47%. Over the past year, the stock has seen a -83.68% change. These figures summarize DRMA's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 2.29 | 4.66 | 4.66 | 6.22 | 63.33 | 4.66 |
| Low | 1.21 | 1.21 | 1.21 | 1.21 | 0.5739 | 1.21 |
| Performance | +19.23% | -5.65% | -45.34% | -68.77% | -83.68% | -6.47% |
According to current financial data, DRMA stock's P/E (TTM) ratio is -0.18, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.23. Key valuation ratios for DRMA, including P/S (N/A), P/B (0.40), and P/FCF (-0.11), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | DRMA | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -0.18 | -1.23 | -5.16 | 32.59 |
| P/S (TTM) | N/A | 3.71 | 464.92 | 5.98 |
| P/B (TTM) | 0.4 | 0.05 | 9.28 | 5.23 |
| P/FCF (TTM) | -0.11 | -142926.32 | -216.68 | 30.63 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep